Juvenile Arthritis News

It may be possible to forecast persistent disease activity in juvenile idiopathic arthritis using C-reactive protein-to-albumin ratio and neutrophil-to-lymphocyte ratio, according to data published in BMC Rheumatology.

In this edition, guselkumab brings ‘stringent’ control through 2 years, SARDs outpatient visits result in opioid prescriptions and more.

ORLANDO, Fla. — Cognitive behavioral therapy can help children and adolescents with rheumatic diseases cope with the challenges of their condition, according to a presenter at the 2024 Rheumatology Nurses Society annual conference.

ORLANDO, Fla. — Allowing children with rheumatic diseases the time and space to formulate their own thoughts on their condition can facilitate communication and help them live a normal life, according to a presenter.

ORLANDO, Fla. — Periodic fever syndromes call for careful documentation, school and work accommodations, and patient education, according to a presenter at the 2024 Rheumatology Nurses Society annual conference.

Tofacitinib’s benefits in patients with juvenile idiopathic arthritis extend through at least 48 months, with no new safety findings, according to data published in Annals of the Rheumatic Diseases.

Fatigue partially mediates the relationship between pain interference and physical disability in juvenile idiopathic arthritis, according to data published in Arthritis Care & Research.

Juvenile arthritis can impact the physical and emotional wellbeing of children in unique ways, manifesting in loneliness and depression, according to the Arthritis Foundation.

“Your foot is very swollen. Like, there’s definitely something really wrong with your foot.”

Most pediatric patients with Sjögren’s disease displayed an interferon signature in their blood and parotid gland tissue, which could help confirm diagnoses and shorten treatment delays, according to data presented at EULAR 2024 Congress.